Research programme: PPAR pan agonists - Chipscreen BiosciencesAlternative Names: CS 204
Latest Information Update: 06 Apr 2010
At a glance
- Originator Chipscreen Biosciences
- Mechanism of Action Peroxisome proliferator-activated receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Metabolic syndrome
Most Recent Events
- 06 Apr 2010 Discontinued for Metabolic syndrome in China (unspecified route)
- 15 Aug 2007 Early research in Metabolic syndrome in China (unspecified route)